30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

V. Bryan Lawlis

Track

Insider profile

Currently holds positions in Biomarin Pharmaceutical Inc, Geron Corp and Coherus Oncology Inc

Performance

Overall performance
3.1
Performance over holding periods
3.1
30 days 90 days 120 days
Average return 38% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
1 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director Biomarin Pharmaceutical Inc June 7, 2007 -
Independent Director Geron Corp March 13, 2012 -
Independent Director Coherus Oncology Inc May 1, 2014 -
Director Humanigen Inc Aug. 7, 2013 - Oct. 10, 2014
V. Bryan Lawlis's trades of Geron Corp's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-05-13 2025-05-09
US Geron Corp (GERN)
B Purchase
23,533 +34.5%
242.44
US$2,231,583 		23,533 +34.5% 242.44 US$2,231,583
2024-05-30 2024-05-30
PrS Proposed sale
5,295
295.29
US$4,193,948 		5,295 295.29 US$4,193,948
2024-05-17 2024-05-15
US Geron Corp (GERN)
PlS Planned sale
42,600 +28.5%
486.31
US$1,303,536 		42,600 +28.5% 486.31 US$1,303,536
2024-05-15 2024-05-15
US Geron Corp (GERN)
PrS Proposed sale
35,000
3.75
US$131,274 		35,000 3.75 US$131,274
2023-05-11 2023-05-11
US Geron Corp (GERN)
PrS Proposed sale
35,000
3.00
US$105,000 		35,000 3.00 US$105,000
2023-05-11 2023-05-11
US Geron Corp (GERN)
PlS Planned sale
35,000 -100.0%
3.00
US$105,000 		35,000 -100.0% 3.00 US$105,000
2023-04-04 2023-04-03
PlS Planned sale
8,500 -22.7%
97.09
US$825,265 		8,500 -22.7% 97.09 US$825,265
2023-04-03 2023-04-03
PrS Proposed sale
8,500
97.09
US$825,265 		8,500 97.09 US$825,265
2022-04-18 2022-04-14
PlS Planned sale
4,250 -15.1%
83.66
US$355,555 		4,250 -15.1% 83.66 US$355,555
2022-01-19 2022-01-14
PlS Planned sale
4,250 -15.1%
87.61
US$372,342 		4,250 -15.1% 87.61 US$372,342
2021-04-19 2021-04-15
PlS Planned sale
7,500 -28.5%
76.90
US$576,750 		7,500 -28.5% 76.90 US$576,750
2021-02-18 2021-02-16
PlS Planned sale
7,500 -28.5%
87.41
US$655,575 		7,500 -28.5% 87.41 US$655,575
2020-06-09 2020-06-05
PlS Planned sale
4,430 -19.0%
107.46
US$476,048 		4,430 -19.0% 107.46 US$476,048
2020-03-18 2020-03-17
PlS Planned sale
3,750 -16.5%
75.39
US$282,712 		3,750 -16.5% 75.39 US$282,712
2020-03-18 2020-03-16
PlS Planned sale
4,610 -19.5%
76.52
US$352,757 		4,610 -19.5% 76.52 US$352,757
2019-09-18 2019-09-17
PlS Planned sale
3,750 -13.7%
74.47
US$279,262 		3,750 -13.7% 74.47 US$279,262
2019-06-19 2019-06-17
PlS Planned sale
3,750 -13.7%
81.08
US$304,050 		3,750 -13.7% 81.08 US$304,050
2019-03-29 2019-03-27
PlS Planned sale
2,150 -10.1%
89.76
US$192,984 		2,150 -10.1% 89.76 US$192,984
2016-06-21 2016-06-20
PlS Planned sale
550 -3.8%
82.77
US$45,524 		550 -3.8% 82.77 US$45,524